Nightfood (NGTF) subsidiary TechForce Robotics enters joint development deal with Oncotelic (OTLC) for pharma robotics

NightFood Holdings, Inc.

TechForce Robotics and Oncotelic will jointly develop AI-enabled, GMP-compliant robotic systems for pharma manufacturing.
Agreement term: initial 1 year, auto-renewing for 5-year terms unless terminated.
IP: AI foreground owned by Oncotelic; robotic hardware owned by TechForce; jointly developed IP jointly owned; all data owned by TechForce.
Revenue sharing, royalty, and profit terms to be negotiated in a separate Commercialization Agreement before first commercial sale.
TechForce is wholly owned by Nightfood Holdings (NGTF); Oncotelic trades as OTLC.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NightFood Holdings, Inc. entered into Joint Development, Manufacturing and Licensing Agreement with Oncotelic Therapeutics, Inc. (effective 2026-03-31).

Action: entry
Agreement: collaboration
Counterparty: Oncotelic Therapeutics, Inc.
Effective: 2026-03-31

Exact text from the filing

On March 31, 2026, Nightfood Holdings, Inc. (the “Company”), wholly owned subsidiary, TechForce Robotics, Inc. (“TechForce”), entered into a Joint Development, Manufacturing and Licensing Agreement (the “Agreement”) with Oncotelic Therapeutics, Inc., (“Oncotelic”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

NightFood Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-015242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.